TAZVERIK™ Has Received FDA Accelerated Approval for Epithelioid Sarcoma
source: pixabay.com

TAZVERIK™ Has Received FDA Accelerated Approval for Epithelioid Sarcoma

  According to a January 2020 release by Business Wire, the USFDA has awarded accelerated approval of Epizyme’s TAZVERIK™ in the treatment of advanced epithelioid sarcoma (ES). The approval was…

Continue Reading TAZVERIK™ Has Received FDA Accelerated Approval for Epithelioid Sarcoma

FDA Agrees to Priority Review of Epithelial Sarcoma Drug Candidate Tazemetostat

According to a publication from Specialty Pharma Times, the American Food and Drug Administration (FDA) has granted priority review to Tazemetostat, Epizyme, Inc's epithelioid sarcoma drug candidate. About Epithelioid Sarcoma…

Continue Reading FDA Agrees to Priority Review of Epithelial Sarcoma Drug Candidate Tazemetostat

Against the Odds: Maria’s Journey with – and beating – Rare Epithelioid Sarcoma

Wisconsin; the land of beer, cheese, good-hearted people, and Maria Voermans - rare cancer survivor and now fierce advocate for the rare disease community.  Ten years ago, Maria had the…

Continue Reading Against the Odds: Maria’s Journey with – and beating – Rare Epithelioid Sarcoma
Close Menu